Drug Type Small molecule drug |
Synonyms ADX 10061, CEE 310, CEE-03-310 + [5] |
Target |
Action antagonists |
Mechanism D1 receptor antagonists(Dopamine D1 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H20N2O4 |
InChIKeyXZPSYCOYKJRHKE-MRXNPFEDSA-N |
CAS Registry128022-68-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Tobacco Use Disorder | Phase 2 | United States | 23 Dec 2004 | |
| Tobacco Use Disorder | Phase 2 | Global | 23 Dec 2004 | |
| Tobacco Use Disorder | Phase 2 | United Kingdom | 23 Dec 2004 | |
| Sleep Initiation and Maintenance Disorders | Phase 2 | - | 02 Feb 2002 | |
| Sleep Initiation and Maintenance Disorders | Phase 2 | - | 02 Feb 2002 | |
| Schizophrenia | Preclinical | Denmark | - |





